Evaluating proposals

Innovative therapies for skin diseases

Maximising the value of your preclinical assets to find a breakthrough therapy for patients.

Our Aim

We are looking for partnering opportunities on new assets (small molecules, biologics or advanced therapies) in research or preclinical development stages that could be useful for the treatment of dermatological diseases.

Preferably, the assets should target immuno-inflammatory pathways or be suitable for dermato-oncological or rare skin indications, and demonstrate strong scientific rationale, including in vitro and in vivo evidences of efficacy, if available.

Our interest

New assets in advanced research or preclinical development stages

What we offer

Access to our expertise in dermatological R&D

Your benefit

Funding and partnership opportunity

Shared goal

Finding innovative therapies for patients

Who is this for?

Universities

Biotechs

Public and private research institutions

Start-ups

Pharmaceutical companies

Collaborative framework

Submitted proposals may be eligible for funding and a research or preclinical development partnership

You will retain ownership of any intellectual property you may bring or develop

Assets might be characterised on key dermatological in vitro and in vivo assays

A designated contact person will help answer your questions

Submitted proposals may be eligible for funding and a research or preclinical development partnership

You will retain ownership of any intellectual property you may bring or develop

Assets might be characterised on key dermatological in vitro and in vivo assays

A designated contact person will help answer your questions

Collaboration process

1 2 3 Proposal submission From July 5th, 2021 to October 31st, 2021 Submissions will be handled following all applicable local compliance requirements Proposal evaluation and selection Within 4-8 weeks after submission

Collaboration process

1

Proposal submission

From July 5th, 2021 to October 31st, 2021

2

Submissions will be handled following all applicable local compliance requirements

3

Proposal evaluation and selection

Within 4-8 weeks after submission

Innovative therapies for skin diseases